Results 41 to 50 of about 1,997 (174)

Letter in Response to “Lomitapide: A Medication Use Evaluation and a Formulary Perspective” by Esba and Alharbi [PDF]

Global Journal on Quality and Safety in Healthcare
Dirk J. Blom
doaj   +2 more sources

Xanthomas Regression in an 8-Year-Old Boy Treated With Lomitapide

JACC: Case Reports, 2019
This case reports on an 8-year-old boy with homozygous familial hypercholesterolemia with large tuberous xanthomas over his hands, elbows, buttocks, knees, and feet.
Genovefa Kolovou, MD, PhD, Aleksandros Tsoutsinos, MD, Irene Mastorakou, MD, MSc, PhD, Sophie Mavrogeni, MD, PhD, George Hatzigeorgiou, MD   +4 more
doaj   +1 more source

THE CURIOUS CASE OF LOMITAPIDE [PDF]

, 2015
Lomitapide is a new Microsomal transfer protein inhibitor. It has been approved as an orphan drug for treating homozygous familial hypercholetelemia. The drug went through various see-saw phases in its brief life.
Syed, Shariq Naeem, Dahiya, Akhil, Misra, Piyush, Roy, Vandana   +3 more
core   +1 more source

Unlocking the therapeutic potential of RNA splicing in lung fibrosis: Insights from the SRSF7–PKM axis [PDF]

Acta Pharmaceutica Sinica B
Bi-Sen Ding
doaj   +2 more sources

Long-term experience with lomitapide treatment in patients with homozygous familial hypercholesterolemia: Over 10 years of efficacy and safety data.

Journal of Clinical Lipidology
BACKGROUND Homozygous familial hypercholesterolemia (HoFH) is a rare disease characterized by loss of low-density lipoprotein receptor (LDLR) function, an extreme elevation of circulating low-density lipoprotein cholesterol (LDL-C) from birth and ...
Marcello Arca, L. D'Erasmo, Marina Cuchel, Dirk J. Blom, J. Cegla, P. Duell, Raul D. Santos, Sallyann O'Brien   +7 more
semanticscholar   +1 more source

Lomitapide-induced fatty liver is a reversible condition: Evidence from a case of familial chylomicronemia syndrome.

Journal of Clinical Lipidology
Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder characterized by severe hypertriglyceridemia. It is caused by loss-of-function variants in the genes encoding the lipoprotein lipase (LPL) enzyme and its cofactors, which ...
D. Tramontano, M. Di Martino, F. Baratta, A. Di Costanzo, N. Cocomello, Daniela Commodari, Simone Bini, I. Minicocci, Marcello Arca, L. D'Erasmo   +9 more
semanticscholar   +1 more source

Lomitapide: a novel drug for homozygous familial hypercholesterolemia [PDF]

, 2014
Lomitapide (Juxtapid® and Lojuxta®; Aegerion Pharmaceuticals, Inc., MA, USA), an orally administered inhibitor of the microsomal triglyceride transfer protein, inhibits the synthesis and secretion of ApoB-containing lipoproteins and, thus, reduces plasma
AVERNA, Maurizio, CEFALU', Angelo Baldassare, Panno, MD   +2 more
core   +1 more source

Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study.

The Lancet Diabetes and Endocrinology
BACKGROUND Homozygous familial hypercholesterolaemia (HoFH) is a rare inherited disorder characterised by extremely high concentrations of LDL cholesterol, leading to early-onset atherosclerosis.
Luis Masana, Alberto Zambon, C. Schmitt, C. Taylan, J. Driemeyer, Hofit Cohen, P. Buonuomo, A. Alashwal, M. Al-Dubayee, Naji Kholaif, J. Díaz-Díaz, Faouzi Maatouk, Sergio Martínez-Hervás, Brian Mangal, S. Löwe, T. Cunningham   +15 more
semanticscholar   +1 more source

Effectiveness and safety of lomitapide in a patient with familial chylomicronemia syndrome

, 2021
Background: Familial chylomicronemia syndrome (FCS) is characterized by severe fasting hypertriglyceridemia, abdominal pain, and recurrent acute pancreatitis. Available triglyceride-lowering drugs are insufficient to avoid pancreatitis.
Cefalu AB, Barbagallo CM, Cabibi D, Giammanco A, Noto D, Spina R, Averna M.   +6 more
core   +1 more source

Treatment Strategy for Dyslipidemia in Cardiovascular Disease Prevention: Focus on Old and New Drugs

Pharmacy, 2018
Prevention and treatment of dyslipidemia should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most.
Donatella Zodda, Rosario Giammona, Silvia Schifilliti   +2 more
doaj   +1 more source